newsfilter
← Latest News
Business Wire·

Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

Follows Signatera’s recent U.S. FDA approval in MIBC and Japanese PMDA approval in CRC Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has submitted an